Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Basics of health technology assessment.
O'Reilly D, Campbell K, Goeree R; Programs for Assessment of Technology in Health Research Institute. O'Reilly D, et al. Among authors: campbell k. Methods Mol Biol. 2009;473:263-83. doi: 10.1007/978-1-59745-385-1_16. Methods Mol Biol. 2009. PMID: 19160744 Review.
Evidence-based decision-making 3: Health technology assessment.
O'Reilly D, Campbell K, Vanstone M, Bowen JM, Schwartz L, Assasi N, Goeree R. O'Reilly D, et al. Among authors: campbell k. Methods Mol Biol. 2015;1281:417-41. doi: 10.1007/978-1-4939-2428-8_25. Methods Mol Biol. 2015. PMID: 25694325
Evidence-Based Decision Making 3: Health Technology Assessment.
O'Reilly D, Audas R, Campbell K, Vanstone M, Bowen JM, Schwartz L, Assasi N, Goeree R. O'Reilly D, et al. Among authors: campbell k. Methods Mol Biol. 2021;2249:429-454. doi: 10.1007/978-1-0716-1138-8_23. Methods Mol Biol. 2021. PMID: 33871857
Effects of study design and trends for EVAR versus OSR.
Hopkins R, Bowen J, Campbell K, Blackhouse G, De Rose G, Novick T, O'Reilly D, Goeree R, Tarride JE. Hopkins R, et al. Among authors: campbell k. Vasc Health Risk Manag. 2008;4(5):1011-22. doi: 10.2147/vhrm.s3810. Vasc Health Risk Manag. 2008. PMID: 19183749 Free PMC article. Review.
Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Assasi N, et al. Among authors: campbell k. Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20384563 Review.
4,391 results